Pompeyo
Viciana
Pompeyo Viciana-rekin lankidetzan egindako argitalpenak (9)
2022
-
Incidence Rate and Risk Factors for Anal Squamous Cell Carcinoma in a Cohort of People Living With HIV from 2004 to 2017: Implementation of a Screening Program
Diseases of the colon and rectum, Vol. 65, Núm. 1, pp. 28-39
2020
-
Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase-or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 1, pp. 200-207
-
Modulation of monocyte activation and function during direct antiviral agent treatment in patients coinfected with HIV and hepatitis C virus
Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 9
-
Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study
Journal of the International AIDS Society, Vol. 23, Núm. 9
2019
-
High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance
Papillomavirus Research, Vol. 7, pp. 62-66
-
High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate-to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex with Men in Low-to-Absent Cytological Abnormalities
Clinical Infectious Diseases, Vol. 69, Núm. 12, pp. 2185-2192
2018
-
Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment
PLoS ONE, Vol. 13, Núm. 10
-
Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients
Journal of Infectious Diseases, Vol. 218, Núm. 4, pp. 624-632
-
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
PLoS ONE, Vol. 13, Núm. 9